Nvidia’s Stock Portfolio: Mixed Q2 Results but Strong Year-to-Date Gains

• Nvidia held stakes in Arm, SoundHound AI, Nano X Imaging, Recursion Pharmaceuticals, and Serve Robotics at the end of the second quarter, Nvidia’s 13F filing this week showed.
• Most of the stocks in Nvidia’s portfolio lost ground during the second quarter, though a majority have still gained since the start of the year.
• Arm, SoundHoundAI, and Serve have climbed at a faster pace than the S&P 500 so far this year, while Nano X Imaging lagged with a 13% gain, and Recursion Pharmaceuticals dropped nearly 32%.

In the second quarter, most stocks in Nvidia’s portfolio saw declines, though a majority have still posted gains since the beginning of the year. According to Nvidia’s latest 13F filing with the SEC, the company held shares in Arm (ARM), SoundHound AI (SOUN), Nano X Imaging (NNOX), Recursion Pharmaceuticals (RXRX), and Serve Robotics (SERV) as of the end of Q2.

Q2 Performance: Arm Outperforms While Others Struggle

Nvidia maintained its shareholdings in Arm, SoundHound AI, Nanox Imaging, and Recursion Pharmaceuticals while adding a new stake in Serve Robotics, which debuted on the Nasdaq in April. During Q2, Arm was the standout performer, rising about 30%, while the other holdings experienced declines. Nano X Imaging and Recursion Pharmaceuticals dropped around 25%, SoundHound AI fell 32%, and Serve Robotics lost about half of its value from its IPO price.

Year-to-Date Gains: Nvidia’s Portfolio Outpaces the Market

Despite Q2 setbacks, most of Nvidia’s holdings have recorded significant gains in 2024, outperforming the S&P 500’s 16.5% rise. SoundHound AI shares have more than doubled, Arm surged 73%, and Nano X Imaging rose 13% by Friday’s close. Serve Robotics has nearly tripled from its IPO price, boosted by a partnership with Shake Shack through Uber Eats. Recursion Pharmaceuticals was the only holding to post a year-to-date loss, down nearly 32%.